CarelabsLtd Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for CarelabsLtd.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare Services earnings growth	30.2%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

There Is A Reason Carelabs Co.,Ltd's (KOSDAQ:263700) Price Is Undemanding

Nov 12

The Market Doesn't Like What It Sees From Carelabs Co.,Ltd's (KOSDAQ:263700) Revenues Yet

Aug 07

We Think CarelabsLtd (KOSDAQ:263700) Has A Fair Chunk Of Debt

Jun 12

Carelabs Co.,Ltd (KOSDAQ:263700) Held Back By Insufficient Growth Even After Shares Climb 50%

Feb 27

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CarelabsLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A263700 - Analysts future estimates and past financials data (KRW Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	81,300	-20,625	11,695	12,135	N/A
6/30/2024	80,502	-24,327	-9,205	-8,684	N/A
3/31/2024	81,181	-23,662	-10,388	-9,952	N/A
12/31/2023	81,827	-24,470	-12,536	-10,620	N/A
9/30/2023	82,468	-26,232	-14,897	-12,175	N/A
6/30/2023	85,203	-24,466	-9,741	-4,744	N/A
3/31/2023	87,341	-26,659	-10,090	-5,370	N/A
12/31/2022	87,607	-26,124	-10,170	-6,240	N/A
9/30/2022	91,259	-13,679	-8,010	-1,615	N/A
6/30/2022	93,658	-8,170	-905	4,209	N/A
3/31/2022	95,413	-1,682	-43,923	2,116	N/A
12/31/2021	93,934	1,253	-41,828	4,297	N/A
9/30/2021	89,878	2,251	-37,175	5,450	N/A
6/30/2021	85,358	3,635	-38,278	4,094	N/A
3/31/2021	79,520	5,377	8,250	10,117	N/A
12/31/2020	76,666	4,329	9,558	11,302	N/A
9/30/2020	73,495	4,234	7,064	8,807	N/A
6/30/2020	71,239	2,761	5,444	6,980	N/A
3/31/2020	70,613	1,626	3,509	5,088	N/A
12/31/2019	68,300	583	1,884	4,455	N/A
9/30/2019	66,419	1,189	-5,034	3,806	N/A
6/30/2019	64,452	1,819	-8,694	1,176	N/A
3/31/2019	58,379	2,109	-6,917	2,620	N/A
12/31/2018	54,379	3,554	-5,173	3,600	N/A
9/30/2018	49,548	4,453	260	3,180	N/A
6/30/2018	45,004	4,456	N/A	6,165	N/A
3/31/2018	42,684	4,849	N/A	5,149	N/A
12/31/2017	39,336	4,788	N/A	2,922	N/A
9/30/2017	37,314	4,999	N/A	3,392	N/A
12/31/2016	18,597	1,935	N/A	2,632	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A263700's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if A263700's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A263700's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A263700's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A263700's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A263700's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/29 06:05
End of Day Share Price	2024/12/27 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Carelabs Co.,Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jongsun Park	Eugene Investment & Securities Co Ltd.

CarelabsLtd Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

New minor risk - Share price stability

There Is A Reason Carelabs Co.,Ltd's (KOSDAQ:263700) Price Is Undemanding

Second quarter 2024 earnings released: ₩255 loss per share (vs ₩227 loss in 2Q 2023)

The Market Doesn't Like What It Sees From Carelabs Co.,Ltd's (KOSDAQ:263700) Revenues Yet

We Think CarelabsLtd (KOSDAQ:263700) Has A Fair Chunk Of Debt

Full year 2023 earnings released: ₩1,289 loss per share (vs ₩1,455 loss in FY 2022)

New major risk - Financial position

Carelabs Co.,Ltd (KOSDAQ:263700) Held Back By Insufficient Growth Even After Shares Climb 50%

New minor risk - Share price stability

Wonik Holdings Co., Ltd (KOSDAQ:A030530) completed the acquisition of 23.27% stake in Carelabs Co.,Ltd (KOSDAQ:A263700) from Citylabs Co.,Ltd. (KOSDAQ:A139050).

Investor sentiment improved over the past week

Carelabs Co.,Ltd announced that it has received KRW 11 billion in funding from PSI International, Inc., NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm

Investor sentiment improved over the past week

New 90-day high: ₩9,570

New 90-day high: ₩9,090

Carelabs Co.,Ltd announced that it has received KRW 20 billion in funding from Mirae Asset Daewoo Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm

Carelabs Co.,Ltd announced that it expects to receive KRW 20 billion in funding from Mirae Asset Daewoo Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm

Third quarter 2020 earnings released: EPS ₩134

Carelabs Co.,Ltd announced that it expects to receive KRW 20 billion in funding from PSI International, Inc.

New 90-day low: ₩8,530

DAYLI BlockChain Co.,LTD. (KOSDAQ:A139050) cancelled the acquisition of an unknown stake in Carelabs Co., Ltd. (KOSDAQ:A263700) from Yello O2O Group Inc.

Maple Investment Partners cancelled the acquisition of 33.5% stake in Carelabs Co.,Ltd (KOSDAQ:A263700) from DAYLI BlockChain Co.,LTD. (KOSDAQ:A139050) and Yello Mobile Inc.